GAMB (GAMB) Stock Price & Analysis
GAMB (GAMB) rose 0.00% to USD 1.84 as of July 25, 2026 at 05:19 UTC, according to Nexqual real-time market data.
GAMB last closed at USD 0; the session ranged USD 1.84–1.9 on volume of 272,354 shares. Market capitalization is $64.85M, with a 52-week range of USD 1.63–11.24 (NGM). Source: Nexqual, July 25, 2026 at 05:19 UTC.
Key Statistics (as of July 25, 2026 at 05:19 UTC)
| Price | USD 1.84 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 1.85 |
| Day Range | USD 1.84 – 1.9 |
| 52-Week Range | USD 1.63 – 11.24 |
| Volume | 272,354 shares |
| Market Cap | $64.85M |
| Exchange | NGM |
Technical Analysis (GAMB)
Nexqual's technical model rates GAMB "SELL" based on 2 bullish and 5 bearish signals across 122 daily candles, as of July 25, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.72 (oversold) |
| vs SMA50 | Below (USD 2.41) |
| MACD | -0.2 (negative) |
Analyst Ratings (GAMB)
Wall Street analysts rate GAMB "Buy" based on 7 analysts, with a mean price target of USD 5 (range USD 3–6), per Nexqual as of July 25, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 5 |
| High Target | USD 6 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 6 / 2 / 0 |
Earnings (GAMB)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD 0.03 |
| Revenue Estimate | $37.48M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.09 vs est 0.12 ▼ miss |
| 2025-12-31 | USD 0.3 vs est 0.2 ▲ beat |
| 2025-09-30 | USD 0.26 vs est 0.16 ▲ beat |
| 2025-06-30 | USD 0.37 vs est 0.15 ▲ beat |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financials & Fundamentals (GAMB)
| Total Revenue | $165.25M |
|---|---|
| Revenue Growth (YoY) | -0.50% |
| Gross Margin | +88.44% |
| Operating Margin | +8.96% |
| Profit Margin | -27.44% |
| ROE | -35.62% |
| Debt / Equity | 112.84 |
| Current Ratio | 1.31 |
| Total Cash | $8.96M |
| Total Debt | $120.91M |
| Free Cash Flow | $10.64M |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Financial Health Score (GAMB)
Nexqual rates GAMB's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +30% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 88%, operating 9% |
| Balance Sheet | Mixed — $9M cash vs $121M debt |
| Cash Flow | Solid — FCF $11M, 6% margin |
| Efficiency | Critical — ROE -36%, ROA 6.0% |
Ownership (GAMB)
| Insider Ownership | +37.87% |
|---|---|
| Institutional Ownership | +40.04% |
| Shares Outstanding | 35.25M |
| Float | 19.40M |
| Short % of Float | +4.48% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Leadership (GAMB)
GAMB is led by Kevin McCrystle (age 42), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 05:19 UTC.
| Co-Founder, CEO & Director | Kevin McCrystle (age 42) |
|---|---|
| Co-Founder & Executive Chairman of the Board | Charles Hanson Gillespie (age 42) |
| Chief Financial Officer | Elias Mark (age 45) |
| Vice President of Investor Relations | Peter McGough |
| Senior Vice President of People | Ellen Monaghan (age 40) |
Major Backers & Investors (GAMB)
Notable institutional backers of GAMB include AWM Investment Company, Inc., ClearBridge Investments, LLC, Morgan Stanley, according to Nexqual as of July 25, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| AWM Investment Company, Inc. | 7.08% |
| ClearBridge Investments, LLC | 1.85% |
| Morgan Stanley | 1.83% |
| Legg Mason Global Asset Management Trust-ClearBridge Small Cap Fund | 1.78% |
| Prescott Group Capital Management, L.L.C. | 1.22% |
| Goldman Sachs | 1.2% |
| UBS Group AG | 0.98% |
| Millennium Management | 0.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.86% |
Source: Nexqual, July 25, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XPOF | Xponential Fitness, Inc. | USD 6.32 | ▲ 3.61% |
| AIRS | AirSculpt Technologies, Inc. | USD 4.61 | ▼ 4.36% |
| JBIO | Jade Biosciences, Inc. | USD 20.08 | ▲ 1.16% |
| HRMY | Harmony Biosciences Holdings, I | USD 35.32 | ▲ 1.32% |
| SGHC | Super Group (SGHC) Limited | USD 14.36 | ▼ 0.83% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 05:19 UTC. This page is informational and not investment advice.